Equillium Announces Appointment of Barbara Troupin to Board of Directors
March 01 2022 - 8:00AM
Business Wire
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company focused on developing novel therapeutics to treat severe
autoimmune and inflammatory disorders with high unmet medical need,
today announced the appointment of Barbara Troupin, M.D., to the
Equillium Board of Directors. Dr. Troupin will serve as a member of
the Nominating and Corporate Governance Committee of the Board.
“We are very happy to welcome Dr. Barbara Troupin to the
Equillium Board,” said Dan Bradbury, chairman of the board of
directors of Equillium. “Her experience building and leading
clinical development, medical and regulatory affairs functions, as
well as her background in global strategy and medical and
commercial positioning across multiple therapeutic areas will be
invaluable as Equillium prepares to initiate its Phase 3 study in
acute graft-versus-host disease and expands its clinical programs
with newly acquired assets from Bioniz Therapeutics.”
Dr. Troupin was most recently senior vice president of
Myokardia, leading all medical affairs functions, product
positioning and launch readiness in the U.S. and E.U. for their
first-to-market, precision medicine treatment for hypertrophic
cardiomyopathy. Prior to Myokardia, Dr. Troupin was chief medical
officer at ERX Pharmaceuticals, a clinical-stage company focused on
the discovery and clinical development of innovative drugs to treat
obesity and related metabolic diseases; chief medical officer at
Aquinox, a clinical-stage company developing novel therapeutics for
chronic urological conditions, inflammation, and pain; and chief
medical officer at Apricus Biosciences, a biopharmaceutical company
advancing innovative medicines in urology, endocrinology, and
rheumatology. Prior to Apricus, Dr. Troupin was vice president of
medical affairs at VIVUS.
Dr. Troupin has completed executive education through Harvard’s
Women on Life Science Boards and was selected as a 2019 Women in
Bio Boardroom Ready participant with frequent continuing education
on board leadership. Barbara has a Doctorate in Medicine (M.D.)
from the University of Pennsylvania School of Medicine and
completed her Residency in Family Medicine at SHARP Healthcare in
San Diego. She has a Master’s in Business Administration (M.B.A.)
from The Wharton School of Business and a Bachelor of Arts in
Biochemistry and Cell Biology from University of California.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel immunomodulatory assets targeting
immuno-inflammatory pathways. Itolizumab, a first-in-class
monoclonal antibody that targets the CD6-ALCAM signaling pathway
which plays a central role in the modulation of effector T cells,
that is advancing into a Phase 3 study for patients with acute
graft-versus-host disease (aGVHD) and is in a Phase 1b study for
patients with lupus/lupus nephritis. BNZ-1, a first-in-class
tri-specific cytokine inhibitor that selectively targets IL-2,
IL-9, and IL-15, is Phase 2 ready and expected to begin enrolling
patients in an alopecia areata study in the second half of 2022.
BNZ-2, a bi-specific cytokine inhibitor that selectively targets
IL-15 and IL-21, is ready for clinical development and expected to
begin enrolling patients in a Phase 1 study to include patients
with celiac disease in the second half of 2022.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", “could”, “continue”,
"expect", "estimate", “may”, "plan", "outlook", “future” and
"project" and other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. Because such statements are subject to risks and
uncertainties, many of which are outside of the Company’s control,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such statements
include, but are not limited to statements regarding the potential
benefit of treating patients with aGVHD, uncontrolled asthma, or
lupus/lupus nephritis with itolizumab, Equillium’s plans and
expected timing for developing itolizumab including the expected
timing of initiating, completing and announcing further results
from the EQUATE, EQUIP, and EQUALISE studies, the potential for any
of Equillium’s ongoing or planned clinical studies to show safety
or efficacy, statements regarding the impact of new leadership team
members, Equillium’s anticipated timing of regulatory review and
feedback, Equillium’s cash runway, and Equillium’s plans and
expected timing for developing itolizumab and potential benefits of
itolizumab. Risks that contribute to the uncertain nature of the
forward-looking statements include: uncertainties related to the
abilities of the leadership team to perform as expected;
Equillium’s ability to execute its plans and strategies; risks
related to performing clinical studies; the risk that interim
results of a clinical study do not necessarily predict final
results and that one or more of the clinical outcomes may
materially change as patient enrollment continues, following more
comprehensive reviews of the data, and as more patient data become
available; potential delays in the commencement, enrollment and
completion of clinical studies and the reporting of data therefrom;
the risk that studies will not be completed as planned; Equillium’s
plans and product development, including the initiation and
completion of clinical studies and the reporting of data therefrom;
whether the results from clinical studies will validate and support
the safety and efficacy of itolizumab; changes in the competitive
landscape; uncertainties related to Equillium’s capital
requirements; and having to use cash in ways or on timing other
than expected and the impact of market volatility on cash reserves.
These and other risks and uncertainties are described more fully
under the caption "Risk Factors" and elsewhere in Equillium's
filings and reports, which may be accessed for free by visiting
EDGAR on the SEC web site at http://www.sec.gov and on the
Company’s website under the heading “Investors.” Investors should
take such risks into account and should not rely on forward-looking
statements when making investment decisions. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Equillium undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220301005430/en/
Investor Contact Michael Moore Vice President, Investor
Relations & Corporate Communications 619-302-4431
ir@equilliumbio.com
Media Contacts Aljanae Reynolds Wheelhouse Life Science
Advisors areynolds@wheelhouselsa.com
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Jul 2023 to Jul 2024